Literature DB >> 30956162

Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma.

Louisa Bolm1, Ekaterina Petrova1, Jürgen Weitz2, Felix Rückert3, Uwe A Wittel4, Frank Makowiec4, Hryhoriy Lapshyn1, Peter Bronsert5, Bettina M Rau6, Igor E Khatkov7, Dirk Bausch1, Tobias Keck1, Ulrich F Wellner1, Marius Distler8.   

Abstract

BACKGROUND: Distal cholangiocarcinoma (DCC) is a rare malignancy and validated prognostic markers remain scarce. We aimed to evaluate the role of serum CA19-9 as a potential biomarker in DCC.
METHODS: Patients operated for DCC at 6 high-volume surgical centers from 1994 to 2015 were identified from prospectively maintained databases. Patient baseline characteristics, surgical and histopathological parameters, as well as overall survival after resection were assessed for correlation with preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 (CA19-9). Preoperative CA19-9 to bilirubin ratio (CA19-9/BR) was classified as elevated (≥ 25 U/ml/mg/dl) according to the upper serum normal values of CA19-9 (37 U/ml) and bilirubin (1.5 mg/dl) giving a cut-off at ≥ 25 U/ml/mg/dl.
RESULTS: In total 179 patients underwent resection for DCC during the study period. High preoperative CA19-9/BR was associated with advanced age and regional lymph node metastases. Median overall survival after resection was 27 months. Elevated preoperative serum CA19-9/bilirubin ratio (HR 1.6, p = 0.025), T3/4 stage (HR 1.8, p = 0.022), distant metastasis (HR 2.5, p = 0.007), tumor grade (HR 1.9, p = 0.001) and R status (HR 1.7, p = 0.023) were identified as independent negative prognostic factors following multivariable analysis.
CONCLUSION: Elevated preoperative bilirubin-adjusted serum CA19-9 correlates with regional lymph node metastases and constitutes a negative independent prognostic factor after resection of DCC.
Copyright © 2019 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 30956162     DOI: 10.1016/j.hpb.2019.03.363

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  11 in total

1.  Preoperative Alkaline Phosphatase-adjusted CA19-9 as a Superior Prognosticator for Extrahepatic Biliary Tract Cancer With Jaundice.

Authors:  Shinichi Ikuta; Tsukasa Aihara; Takayoshi Nakajima; Meidai Kasai; Naoki Yamanaka
Journal:  Cancer Diagn Progn       Date:  2022-09-03

2.  Prognostic Significance of Growth Pattern in Predicting Outcome of Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand.

Authors:  Waritta Kunprom; Chaiwat Aphivatanasiri; Prakasit Sa-Ngiamwibool; Sakkarn Sangkhamanon; Piyapharom Intarawichian; Walailak Bamrungkit; Malinee Thanee; Piya Prajumwongs; Watcharin Loilome; Narong Khuntikeo; Attapol Titapun; Apiwat Jareanrat; Vasin Thanasukarn; Tharatip Srisuk; Vor Luvira; Kulyada Eurboonyanun; Julaluck Promsorn; Supinda Koonmee
Journal:  Front Public Health       Date:  2022-05-16

3.  Ratio of CA19-9 level to total bilirubin as a novel prognostic indicator in patients with pancreatic head carcinoma following curative resection.

Authors:  Wen-Li Xu; Jing Wang; Shao-Cheng Lyu; Lin Zhou; Qiang He; Ren Lang
Journal:  Gland Surg       Date:  2021-03

4.  Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study.

Authors:  Jae Pil Hwang; Jong Ho Moon; Hee Kyung Kim; Min Hee Lee; Chae Hong Lim; Soo Bin Park; Joon-Kee Yoon; Jung Mi Park
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

5.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375

6.  Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center.

Authors:  Jiayi Li; Qiao Chen; Bao Jin; Yue Shi; Xiangan Wu; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Yilei Mao; Xinting Sang
Journal:  Cancer Manag Res       Date:  2020-01-20       Impact factor: 3.989

7.  Prognostic Value of Carbohydrate Antigen 19-9 and the Surgical Margin in Extrahepatic Cholangiocarcinoma.

Authors:  Ryusei Yamamoto; Teiichi Sugiura; Ryo Ashida; Katsuhisa Ohgi; Mihoko Yamada; Shimpei Otsuka; Katsuhiko Uesaka
Journal:  Ann Gastroenterol Surg       Date:  2021-11-09

8.  Proposal of the optimal numbers of examined and positive lymph nodes to the 8th edition of American Joint Committee on Cancer (AJCC) staging for 758 patients with distal cholangiocarcinoma.

Authors:  RuiYang Wu; Gang Zhang; Jiao Feng; Liang Zhang; ZhiMing Yang
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

9.  Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria.

Authors:  Casper van Eijck; Stefan Löb; Friedrich Anger; Anna Döring; Jacob van Dam; Johan Friso Lock; Ingo Klein; Max Bittrich; Christoph-Thomas Germer; Armin Wiegering; Volker Kunzmann
Journal:  Ann Surg Oncol       Date:  2020-09-12       Impact factor: 5.344

10.  The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.

Authors:  Lenka N C Boyd; Mahsoem Ali; Laura Kam; Jisce R Puik; Stephanie M Fraga Rodrigues; Eline S Zwart; Freek Daams; Barbara M Zonderhuis; Laura L Meijer; Tessa Y S Le Large; Elisa Giovannetti; Hanneke W M van Laarhoven; Geert Kazemier
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.